The COVID-19 antibody even works on all new mutant strains.
Even as the nightmare with deadly new varieties of COVID-19 began to make people gloomy, the arrival of the vaccines changed the gloomy narrative and sparked a lot of optimism.
COVID-19 antibody discovered that can neutralize all known SARS-CoV-2 strains
However, the need for treatments for people at high risk for serious illness after infection with COVID-19 and for people with weak immune systems who may not produce a robust response to the vaccines has always been felt. Significant progress has been made in the development of effective antibody-based therapies in the past few months. Currently, three such drugs have received emergency approval from the US Food and Drug Administration.
One such drug, sotrovimab, was developed by GlaxoSmithKline and Vir Biotechnology after a large joint study by scientists in 2003 found a natural antibody in the blood of a SARS survivor that has remarkable breadth and effectiveness.
This antibody is called S309. Experiments showed that it neutralized all known SARS-CoV-2 strains, including the newly emerged mutants that can now “escape” from previous antibody therapies, as well as the closely related original SARS-CoV virus.
According to a report in SciTechDaily, Jay Nix, head of the Molecular Biology Consortium based at Berkeley Lab’s Advanced Light Source (ALS), performed an X-ray crystallography on antibody samples from survivors early in the study. This helped make structural maps like this one Antibodies with the SARS-CoV-2 spikeProtein fusing, which in turn allowed developers to choose the most promising antibodies. According to the laboratory results, they developed sotrovimab.
In May, the FDA approved emergency sotrovimab after studies showed that hospitalization or death rates in people with mild to moderate COVID-19 infections who underwent therapy were 85 percent lower than placebo became.
However, since new mutations could arise, the researchers started a follow-up study to further investigate such antibodies. In doing so, they identified an antibody with unprecedented effectiveness. Nix said this antibody “appears to neutralize all known Sarbecoviruses – the type of coronavirus that causes respiratory infections in mammals”, making it “harder for a new strain to escape.”